Connection

DAVID G MENTER to Cetuximab

This is a "connection" page, showing publications DAVID G MENTER has written about Cetuximab.
Connection Strength

0.183
  1. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2017 Aug 01; 23(15):4146-4154.
    View in: PubMed
    Score: 0.125
  2. MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. 2016 08 23; 7(34):54627-54631.
    View in: PubMed
    Score: 0.030
  3. ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development. Cancer Cell. 2015 Aug 10; 28(2):183-97.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.